DNV3837 From my news feed: #research #clinicaltrials news.
The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada.
In Phase II, everyone gets the treatment.
DNV3837 is a narrow-spectrum, hybrid oxazolidinone-quinolone synthetic antibiotic targeting only Gram-positive bacteria.
It is developed as a highly active first-line treatment targeting C. diff.
It’s an IV antibiotic, so it’s good for people with severe diarrhea, for whom oral antibiotics may have trouble staying in the intestines long enough to kill off c-diff. It crosses the GI barrier and goes straight to where the bacteria are to specifically target it where it lives.
Article contains a link to more info on the trials.